COMPANY REGISTRATION NUMBER:
3286288
|
Filleted Financial Statements |
|
|
Statement of Financial Position |
|
31 March 2025
Fixed assets
|
Investments |
4 |
|
250,000 |
250,000 |
|
|
|
|
|
Current assets
|
Debtors |
5 |
632,421 |
|
993,465 |
|
Cash at bank and in hand |
1,202 |
|
13,678 |
|
--------- |
|
------------ |
|
633,623 |
|
1,007,143 |
|
|
|
|
|
|
Creditors: amounts falling due within one year |
6 |
439,941 |
|
813,484 |
|
--------- |
|
------------ |
|
Net current assets |
|
193,682 |
193,659 |
|
|
--------- |
--------- |
|
Total assets less current liabilities |
|
443,682 |
443,659 |
|
|
--------- |
--------- |
|
|
|
|
|
Capital and reserves
|
Called up share capital |
|
76,046 |
76,046 |
|
Share premium account |
|
248,415 |
248,415 |
|
Profit and loss account |
|
119,221 |
119,198 |
|
|
--------- |
--------- |
|
Shareholders funds |
|
443,682 |
443,659 |
|
|
--------- |
--------- |
|
|
|
|
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements were approved by the
board of directors
and authorised for issue on
16 December 2025
, and are signed on behalf of the board by:
Company registration number:
3286288
|
Notes to the Financial Statements |
|
Year ended 31 March 2025
1.
General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Cobham Hospital, 168 Portsmouth Road, Cobham, Surrey, KT11 1HS.
2.
Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4.
Investments
|
Shares in group undertakings |
|
£ |
|
Cost |
|
|
At 1 April 2024 and 31 March 2025 |
250,000 |
|
--------- |
|
Impairment |
|
|
At 1 April 2024 and 31 March 2025 |
– |
|
--------- |
|
|
|
Carrying amount |
|
|
At 31 March 2025 |
250,000 |
|
--------- |
|
At 31 March 2024 |
250,000 |
|
--------- |
|
|
5.
Debtors
|
2025 |
2024 |
|
£ |
£ |
|
Trade debtors |
439,935 |
813,465 |
|
Amounts owed by group undertakings and undertakings in which the company has a participating interest |
192,486 |
180,000 |
|
--------- |
--------- |
|
632,421 |
993,465 |
|
--------- |
--------- |
|
|
|
The amounts owed by group undertakings are payable on demand.
6.
Creditors:
amounts falling due within one year
|
2025 |
2024 |
|
£ |
£ |
|
Amounts owed to group undertakings and undertakings in which the company has a participating interest |
439,936 |
813,466 |
|
Corporation tax |
5 |
18 |
|
--------- |
--------- |
|
439,941 |
813,484 |
|
--------- |
--------- |
|
|
|
The amounts owed to group undertakings are due on demand.
7.
Summary audit opinion
The auditor's report dated
16 December 2025
was
unqualified
.
The senior statutory auditor was
Christopher Cook BA FCA
, for and on behalf of
Cook & Co Accountants LLP
.
8.
Related party transactions
The company is a wholly owned subsidiary of Epsomedical (Acquisitions) Limited. On 29th October 2024 Epsomedical (Acquisitions) Limited became a wholly owned subsidiary of Epsomedical Holdings Limited, a company in which
Ms A R Pearce
is the controlling shareholder. All the Companies are Registered in England and Wales. Both Mr T Taylor and Dr R Cowlard were directors of Epsomedical (Acquisitions) Limited until 30th October 2024, and shareholders of Epsomedical (Acquisitions) Limited until 29th October 2024. Mr T Taylor was also a director of Cobham Day Surgery and Epsom Day Surgery Limited until 29th October 2024. During the year the company purchased goods and services from Cobham Day Surgery Limited of £5,813,846 (2024: £5,130,616). During the year the company purchased goods and services from Epsom Day Surgery Limited of £3,831,077 (2024: £3,723,172). At 31st March 2025 the company owed the following amount: Cobham Day Surgery Limited £290,626 (2024 - £402,407) Epsom Day Surgery Limited £149,309 (2024 - £411,058) At 31st March 2025 the company was owed the following amount: Epsomedical (Acquisitions) Limited £NIL (2024 - £180,000) Epsomedical Holdings Limited £192,486 (2024 - NIL)
9.
Controlling party
The ultimate parent undertaking of the company was Epsomedical (Acquisitions) Limited until 29th October 2024, after which Epsomedical Holdings Limited became the ultimate parent undertaking. Both companies are registered in England and Wales.